moneyheap
SUPN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Supernus, Inc. Common Stock (SUPN) stock moving?
SUPN closed at $28.75 on Nov 10, up about 4% on the day, after a volatile stretch since the Nov 2 merger close. The stock spiked to a $31.62 high on Nov 3, the first session as the combined company, then fell to a $26.16 close on Nov 6 before recovering. Volume was heavy from Oct 29 to Nov 6, peaking at 9.05M shares on Nov 3, and fell to 2.78M on Nov 10, which suggests the initial merger-driven trading is fading. The 30-day range is $25.92 to $31.62.
News behind the analysis
- Supernus Pharmaceuticals CEO to Participate in Fireside Chat at 2026 Jefferies Global Healthcare ConferenceCEO Jack Khattar will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. This is a scheduled investor event with no new financial data.
- Analyst Initiates Coverage on Supernus PharmaceuticalsA market analyst initiated coverage on Supernus with a bullish outlook. The report adds to the recent run of positive initiations.
- B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47B of A Securities started coverage of Supernus with a Buy rating and a $47 price target. That target is about 63% above the Nov 10 close of $28.75.
- This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayAnalysts initiated bullish coverage on several companies, including Supernus, with Buy, Outperform or Overweight ratings and price targets. Supernus is one of five names in the batch.
- Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87Cantor Fitzgerald kept its Overweight rating on Supernus and raised its price target to $87. The target is far above the other published targets.
- Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price TargetPiper Sandler reinstated an Overweight rating on Supernus with a $47 price target. The firm pointed to the strategic benefits of the Indivior merger.
- Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical LeaderSupernus and Indivior completed their merger on November 2, 2026, creating Supernus, Inc. with an 11-product portfolio led by SUBLOCADE. The combined company began trading as SUPN on November 3.
- Supernus Secures $650 Million Senior Secured Term LoanSupernus entered into a $650 million senior secured term loan with Citibank and other lenders. The loan funds the $1.0 billion special cash dividend to Indivior stockholders tied to the merger and adds to the company's debt.
- Supernus Pharmaceuticals Reports Third Quarter 2026 Financial ResultsSupernus reported record third-quarter 2026 total revenues of $226.8 million. The company also reaffirmed the November 2 closing date for the Indivior merger.
- Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M EstSupernus raised its FY2026 sales guidance to $875M-$900M, above the $877.7M consensus estimate. The company also said this guidance is standalone and will no longer apply once the Indivior merger closes.
About Supernus, Inc. Common Stock
Supernus, Inc. is a drugmaker focused on central nervous system conditions. It was formed on November 2, 2026, when Supernus Pharmaceuticals and Indivior Pharmaceuticals completed a merger of equals, and it began trading under SUPN on November 3, 2026. The combination puts Supernus's ADHD, Parkinson's and epilepsy medicines together with Indivior's opioid-addiction treatments.
How it makes money
The company makes money by selling prescription brand-name drugs, mostly in the US. Before the merger, Supernus's sales came from Qelbree (a non-stimulant ADHD drug and its largest growth product), GOCOVRI for Parkinson's (about $43 million in Q3 2026), the epilepsy drugs Trokendi XR and Oxtellar XR (which now face generic competition), the Apokyn Parkinson's product, and Zurzuvae for postpartum depression, which came with the Sage Therapeutics acquisition. Total Q3 2026 revenue was a record of about $227 million. Indivior adds buprenorphine-based opioid use disorder treatments, mainly Sublocade, a monthly injection, along with Suboxone film. The split of revenue across the combined company had not been reported yet.
What usually moves SUPN
- Merger integration and cost savings from the Indivior deal
- Prescription growth for Qelbree and Sublocade
- Generic competition and patent expirations
- Pipeline trial results and FDA decisions
- Drug pricing and insurance coverage policy